Vir Biotechnology (VIR) Liabilities and Shareholders Equity (2018 - 2026)

Vir Biotechnology has disclosed Liabilities and Shareholders Equity across 9 years of filings, most recently posting $1.0 billion for Q1 2026.

• Liabilities and Shareholders Equity for Q1 2026 came in at $1.0 billion, down 21.57% year-over-year; the trailing twelve-month figure through Mar 2026 was $4.2 billion (down 27.82% YoY), and the FY2025 annual result was $1.0 billion, down 28.31% from the prior year.
• Liabilities and Shareholders Equity came in at $1.0 billion for Q1 2026 at Vir Biotechnology, up from $1.0 billion in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $2.9 billion in Q1 2022 to a low of $1.0 billion in Q4 2025.
• The 5-year median for Liabilities and Shareholders Equity is $1.8 billion (2024), against an average of $1.9 billion.
• Across the five-year window, Liabilities and Shareholders Equity soared 154.24% in 2022 and tumbled 32.71% in 2024, its largest moves.
• Vir Biotechnology's Liabilities and Shareholders Equity stood at $2.8 billion in 2022, then sank by 31.51% to $1.9 billion in 2023, then slipped by 27.11% to $1.4 billion in 2024, then dropped by 28.31% to $1.0 billion in 2025, then grew by 2.27% to $1.0 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.0 billion (Q1 2026), $1.0 billion (Q4 2025), and $1.0 billion (Q3 2025), per Business Quant data.